Is docetaxel plus epirubicin versus docetaxel plus capecitabine a more effective combination as a front-line treatment in women with advanced breast cancer?
From: Annals of Oncology
- Mavroudis, D., Papakotoulas, P., Ardavanis, A., Syrigos, K., Kakolyris, S., Ziras, N., Kouroussis, C., Malamos, N., Polyzos, A., Christophyllakis, C., Kentepozidis, N., Georgoulias, V., 2010. Randomized Phase III Trial Comparing Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine as First-Line Treatment in Women with Advanced Breast Cancer. Ann Oncol 21, 48–54.
- 136 previously untreated women with advanced breast cancer
- Patients were randomly assigned to receive docetaxel 75 mg/m2 plus epirubicin 75 mg/m2 on day 1 or docetaxel 75 mg/m2 on day 1 plus capecitabine 950 mg/m2 orally twice daily on days 1–14 in 21-day cycles.
- The primary objective of the study was to compare time to disease progression
- Time to disease progression was 10.6 versus 11.0 months for docetaxel plus epirubicin and docetaxel plus capecitabine respectively.
- Docetaxel plus epirubicin regimen was relatively more toxic resulting in more neutropenia, anemia, asthenia and toxicity-related hospitalizations versus more hand–foot syndrome and nausea– vomiting with the docetaxel plus capecitabine regimen.
- No (with confidence)
- The results indicate that the docetaxel plus epirubicin and docetaxel plus capecitabine regimens have similar efficacy but the docetaxel plus capecitabine regimen is favored because of less non-hematological toxicity.